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Summary
Eukaryotic forms of life have been continually invaded by microbes and
larger multicellular parasites, such as helminths. Over a billion years ago
bacterial endosymbionts permanently colonized eukaryotic cells leading to
recognized organelles with a distinct genetic lineage, such as mitochondria
and chloroplasts. Colonization of our skin and mucosal surfaces with bac-
terial commensals is now known to be important for host health. How-
ever, the contribution of chronic virus and parasitic infections to immune
homeostasis is being increasingly questioned. Persistent infection does not
necessarily equate to exhibiting a chronic illness: healthy hosts (e.g.
humans) have chronic viral and parasitic infections with no evidence of
disease. Indeed, there are now examples of complex interactions between
these microbes and hosts that seem to confer an advantage to the host at
a particular time, suggesting that the relationship has progressed along an
axis from parasitic to commensal to one of a mutualistic symbiosis. This
concept is explored using examples from viruses and parasites, consider-
ing how the relationships may be not only detrimental but also beneficial
to the human host.
Keywords: chronic inflammation; parasitic helminth; tolerance/suppres-
sion/anergy; viral.
Introduction
In humans, infection can result from a variety of organ-
isms including bacteria, viruses, parasites and fungi. Tra-
ditionally, pathogenic infections were defined according
to Koch’s postulates, i.e. they were organisms that could
be ‘found’, isolated, cultured and confirmed as a causative
agent of disease by inoculation into a new host. Apart
from the obvious limitations of pathogen isolation and
culture techniques, Koch’s postulates were criticized and
adapted in the face of technological advances, such as the
identification of pathogen-specific nucleic acids using
molecular biology techniques. With the advent of metage-
nomic sequencing, it has become clear that the presence
of a microbe is not necessarily indicative of pathogenesis
and instead may represent a degree of co-evolution and
symbiosis between the organism and the host.1 Accumu-
lating evidence demonstrates that commensal organisms
colonizing our mucosal surfaces, particularly the gut
microbiome, benefit immune functions at all levels.2
However, opportunistic infections by commensal bacteria
and fungi can also occur, usually in the hospital setting
of patients who are already ill, resulting in severe nosoco-
mial sepsis or pneumonia.
Chronic infections are either persistent or latent infec-
tions within a host. Despite attempts by the immune sys-
tem to respond to the acute infection, pathogens escape
from immune clearance by modulating, or regulating our
immune response. For instance, persistence of an unre-
solved infection can result in immune exhaustion or devi-
ation, for example, by switching of CD4+ T cells to
interleukin-10 (IL-10) producers in patients with chronic
hepatitis C virus (HCV) infection,3 or the induction of
IL-10 and interferon-c co-production by CD4+ T cells
following parasitic Toxoplasma gondii infection.4 The
hijacking of these pathways by pathogens is an effective
way for viruses and parasites to avoid immunopathology
while establishing a persistent or latent infection.5,6 In
some instances, this immune regulation may also be cou-
pled to significant benefits for the host, dampening
underlying inflammatory disorders and resulting in a sur-
vival advantage. Below we will consider examples of this
mutualistic symbiosis, focusing on examples from chronic
viral and parasitic infections.
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Viruses
In the case of viruses, metagenomic sequencing of the ‘vi-
rome’ has identified eukaryotic viruses, including acute
infections, chronic replicating infections and chronic
latent infections. Furthermore, in a complex multicellular
eukaryotic host, the virome also includes bacteriophages
infecting the microbiota, and virus-derived genetic ele-
ments incorporated into eukaryotic chromosomes, e.g.
retrovirus-encoded elements, which are thought to make
up 8% of the genome.7 It is difficult to know how stably
associated the overall virome is with the host, particularly
as viruses relying solely on a lytic life cycle, such as influ-
enza virus, respiratory syncytial virus or dengue virus,
cause cell death but tend to produce short-lived acute
infections. However, non-cytopathic viruses, which do
not cause such profound cell death, can infect and persist
for the lifespan of the host.
It is estimated that humans carry between 8 and 12
persistent viral infections, including herpesviruses, retro-
viruses, Allenoviridae and in fewer individuals: papillo-
maviruses, hepatitis viruses and human
immunodeficiency virus (HIV).8 For most of the life-time
of the host, persistent viral infections cause no overt clini-
cal disease. This pathogen-induced immune regulation is
also employed by other chronic infections, including par-
asites (discussed in the next section), to enhance patho-
gen survival and often confer a survival advantage to the
host. This viral mutualistic symbiosis is well recognized
in invertebrates and plants, for example infection with
cucumber mosaic virus imparts drought resistance to the
Nicotiana benthamiana plant.9 Some viruses operate
through a bacterial go-between to exert a symbiotic effect,
for example aphids are protected from invading wasp lar-
vae by infection with a heritable symbiotic bacteria that
harbours a bacteriophage encoding an anti-wasp toxin.10
In these examples, the virus alters gene expression in the
host and confers an advantage, which in the case of a
chronically infected host, results in an increased chance
of competitiveness and survival.
So can we find examples of mutualistic symbiosis in
human (or vertebrate) hosts? The success of the balance
between the replication and survival of the invading virus
and the immune response and survival of the host can be
defined by four key clinical factors: does the presence of
viral infection lead to tissue, and hence organ, dysfunc-
tion; does the virus compromise the immunity of the
host allowing secondary pathogens to invade; conversely
does the immune system maintain a state of persistent
activation leading to immunopathology; and lastly, is it
possible that a persistent viral infection may in some
manner benefit the host?
Hepatotropic viruses illustrate the complexity of host–
virus relationships.11 Although these viruses grow and
replicate in the liver, some hepatotropic viruses spread by
the oral–faecal route (hepatitis A virus and hepatitis E
virus). They are adapted to rapid host-to-host horizontal
spread by passing from the liver to the gut and the faeces,
using the ideal conduit: the biliary tract. These viruses
have no need to persist in humans. However, hepatitis B
virus (HBV) and HCV are blood-borne infections, whose
natural route of infection is perinatal, from the mother to
the neonate. For these viruses, the chances of transmis-
sion are rarer, and to maximize the likelihood of success,
an ideal scenario is persistent infection accompanied by
high levels of viraemia. After initial infection with HCV,
80% of people develop chronic infection,12 exhibit detect-
able viraemia (ranging from about 103 to 107 copies/ml)
but no evidence of liver disease.13 Both HBV and HCV
have evolved a series of strategies to avoid or evade the
innate and adaptive immune responses, including the
modulation of antigen presentation and expansion of
anti-inflammatory regulatory T cells.14,15 The mainte-
nance of the host in this state provides a circulating reser-
voir of infective virus, increasing the statistical chance of
viral transmission to a new host.
Once chronically infected with HBV or HCV, there is
an astonishingly long period in most hosts, usually of
decades, where there is no detriment to health. In some
individuals attempted immune control of the virus by the
host immune system over time drives liver inflammation
and complications, such as liver cirrhosis or cancer. In
these patients, there is a direct correlation between the
degree of chronic inflammation (in this case the expres-
sion of the natural cytotoxicity receptor NKp46) and stea-
dily worsening liver pathology.16 During chronic
infection, HCV and HBV also employ strategies to escape
from on-going host immunological attack by key adaptive
immune cells such as cytotoxic CD8+ T cells; for instance
mutation of key viral epitopes, presented to these CD8+
T cells by MHC class I molecules.17 Other diverse
immune evasion strategies include interference with the
signalling pathways required for production of pro-
inflammatory cytokines, the up-regulation of inhibitory
molecules such as PD-1 on virus-specific CD8+ T cells
and the expansion of CD4+ regulatory T cells that can
inhibit virus-specific CD8+ T cells (reviewed in Park and
Rehermann18) (Fig. 1.). These modifications can have a
profound impact on the ability of the host to generate an
immune response, or on underlying inflammatory condi-
tions.
As the development of hepatitis virus liver-related ill-
ness usually takes many years and does not impact on
reproductive fitness, the question arises: is there a benefit
of viral immune manipulation on the human host popu-
lation? One possibility is that the infected liver is less
accommodating to other hepatotropic pathogens. Indeed
studies have shown that patients with higher HBV virae-
mia have reduced Plasmodium spp. parasitaemia and
exhibit asymptomatic malaria, characterized by decreased
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inflammatory cytokine production.19 The young children
most likely to become infected with HBV are particularly
susceptible to malaria infection, illness and death, there-
fore viral dampening of this anti-malaria response would
offer a clear selective advantage for the survival and trans-
mission of HBV.
There are over 100 herpesviruses that infect vertebrate
and invertebrate hosts. Eight commonly infect humans:
herpes simplex virus types 1 and 2, varicella zoster virus,
cytomegalovirus (CMV), Epstein–Barr virus (EBV),
human herpesvirus 6, human herpesvirus 7 and Kaposi’s
sarcoma-associated herpesvirus. All herpesviruses can
establish latent infection within specific niches (e.g. nerve
cells for herpes simplex virus, haematological cells for
EBV, epithelial cells for CMV) and induce a systemic
immune response. Immune control of these viruses, and
the dynamics of viruses moving between latency and reac-
tivation, results in fluctuating local and systemic inflam-
matory responses, which may result in injury and damage
of infected tissues or a gradual deterioration of the
immune system. A case in point is CMV infection of
endothelial cells, where CMV-induced effector T cells
cause endothelial cell damage and low-grade long-term
vascular injury.20 CMV can have a profound impact on
the T-cell compartment of the host immune system, driv-
ing bursts of functional CMV-specific memory CD8+ T-
cell expansion during chronic infection.21 Although the
establishment and maintenance of these inflated T-cell
populations in adults is thought to be critical for the con-
trol of persistent viral infection, it is currently unclear
how this process impacts on host immune responses to
other pathogens and vaccines in otherwise healthy indi-
viduals. Immunosuppressive medical treatment of
immunocompromised patients infected with CMV, can
lead to virus-related clinical disease, such as CMV colitis,
hepatitis or organ rejection. Underlying CMV infection or
the opportunistic outgrowth of viral or bacterial com-
mensal species results in loss of immune responsiveness
or containment in these patients.22 The acquisition of
CMV during early life has a profound impact on the
immune cell subset composition of infants.23 Although
controversial, some suggest that the natural acquisition of
CMV infection by young children may prime and boost
the adaptive immune system, moulding it for later life.24
Herpesviruses have evolved an extraordinary ability to
persist and escape immune detection by dedicating much
of their large genomic capacity to subverting a diverse
array of innate and adaptive immune responses. A major
strategy for viral immune evasion is to target the initia-
tion of the host immune response, by inhibiting host
MHC class I antigen presentation of virus-specific epi-
topes to anti-viral cytotoxic CD8+ T cells.25 To counteract
the possible increased natural killer cell killing of infected
cells associated with loss of MHC class I, the machinery
that alerts these cells is also dismantled by the virus26
(Fig. 1). However, during chronic Kaposi’s sarcoma-asso-
ciated herpesvirus infection, the inhibition of antigen pre-
sentation by the virus can lead to the development of the
endothelial tumour Kaposi’s sarcoma, particularly in
immunocompromised patients.27.
For the vast majority of us who live harmoniously with
these viruses, again the question arises: is there a fitness
benefit for the host? Evidence from animal models
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Figure 1. The good (light) and bad (dark) side of chronic virus infec-
tion. Infection of tissues by viruses and subsequent chronic inflamma-
tion can lead to tissue damage, e.g. hepatitis. In chronic hepatitis C
virus (HCV) infection, progression to disease is associated with the
expression of the natural killer (NK) cell receptor NKp46. Many other
viruses directly infect antigen-presenting cells (APCs) or have a num-
ber of molecules that can down-regulate MHC class I expression
expressed by these cells; this molecule is important for viral recogni-
tion by CD8+ T cells but is also important for elimination of tumour
cells. The NK cell killing of cells expressing low MHC class I is pre-
vented by the dismantling of NK activating receptors. viral inter-
leukin-10 (vIL-10) can transform B cells and help the virus to
establish a chronic infection. This molecule is also reported to reduce
autoimmunity, inflammation and tissue rejection. Chronic virus
infection can promote anti-inflammatory responses, including the
expansion of regulatory T (Treg) cells and, production of transform-
ing growth factor-b (TGF-b) and is associated with a switch from
interferon-c (IFN-c) to IL-10-producing CD4+ T cells. Viral infection
is also able to reduce antigen presentation and activation of APCs,
reducing CD4+ T-cell activation and inflammatory responses.
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suggests that the presence of persistent latent (but not
lytic) c-herpesvirus infection can confer protection from
lethal bacterial infection and lethal lymphoma challenge.
Protection was associated with increased macrophage
activation and the production of the antiviral cytokine
interferon-c28 or increased natural killer cell activity.29
Latent viral infection could also significantly delay type 1
diabetes onset in mice by reducing antigen presentation
of autoantigen to CD4+ T cells.30 Increases in the produc-
tion of interferon-c during latent viral infection may
underlie protection from other types of inflammatory dis-
ease, as supported by epidemiological data demonstrating
inverse associations between herpesvirus infection31,32 and
‘type-2’ allergic diseases. This skewing of the T helper
type 1–type 2 balance will be considered in the following
section focusing on the possible protective effects of
chronic parasitic infection. Animal models have also
shown that viral cytokine homologues, such as EBV IL-10
can provide some benefit to the host. EBV IL-10 can act
on multiple cell types and inhibit cytokine synthesis by
natural killer and T cells.33 The molecule is thought to
play a critical role in the transformation of B cells,
enabling time for the virus to establish latency.34 How-
ever, it has also been shown to inhibit collagen-induced
arthritis, autoimmune diabetes and pancreatitis, and to
improve survival following sepsis and graft acceptance
when expressed or administered in vivo35 (Fig. 1.). These
examples demonstrate viral mutualistic symbiosis, as
described above for other non-vertebrate eukaryotes.
The study of mutualistic symbiosis allows us to view
millions of years of host–pathogen co-evolution. With
increased movement of humans around the globe, we are
also witnessing emerging new virus infections almost
annually, often derived from animal reservoirs. Recog-
nized in the 1980s, HIV has already provided evidence of
pathogen-driven selection. Natural elite controllers are
found in ~ 3/1000 of untreated HIV-infected individuals
and are defined by stable CD4+ T-cell count with very
low viral loads; these patients demonstrate superior anti-
viral CD4+ T-cell36 and cytotoxic CD8+ T-cell
responses.37 If effective anti-retroviral treatment was not
available, it seems inevitable that pathogen-driven natural
selection would favour these elite controllers, increasing
the population frequencies of beneficial genetic polymor-
phisms such as HLA-B27, HLA-B51 and HLA-B57.38
Polymorphisms such as HLA-B27 also promote CD8+ T-
cell clearance of HCV but are strongly linked to develop-
ment of the autoimmune disease ankylosing spondylitis.
Interestingly, some suggest that Plasmodium falciparum
infection may have contributed to negative selection of
this gene, due to the greater susceptibility of patients
expressing this allele to severe forms of malaria.39 Genetic
selection, the moulding of our immune response and sub-
sequent susceptibility to disease, has occurred as a result
of ancient long-standing infections by chronic pathogens,
those causing malaria, leprosy, as well as parasitic worms
(discussed in the next section).40.
Parasites
Helminths affect over one billion people worldwide,
mostly within developing regions, such as sub-Saharan
Africa, South America and India. Although new epidemi-
ological studies are required, a systematic review in 2011
demonstrated that soil-transmitted helminths are also
prevalent in high-income countries.41 Helminth infections
have co-evolved with man and evidence suggests that in a
similar manner to chronic viral infections (discussed in
the previous section), they have provided selective pres-
sure on the genetic make-up of the host.42 Helminth
infections are acquired in childhood; however, in high-
income countries zoonotic helminth infections of adults
from cats and dogs are most common. Infection can
cause diarrhoea, abdominal pain, weakness and anaemia
and contributes to 14 million disability-adjusted life-years
(or the cumulative number of years lost to ill-health, dis-
ability or early death).43 For orally transmitted helminths,
mortality is rare and infection is often asymptomatic;
most patients exhibiting low worm burden and limited
clinical pathology.44.
Although gastrointestinal and intravascular helminth
infections are reported to have some beneficial effects on
inflammation-induced pathology in response to co-infec-
tion with other parasites,45 bacterial pathogens46 or viral
infections,47 it can also impair protective immunity to
concurrent parasite infections,48–51 promoting anaemia
and liver pathology following malaria infection,52–54 exac-
erbating Citrobacter rodentium infection and associated
bacterial-induced colitis55 and aggravating virus-related
liver disease.56 This parasite impairment of host immu-
nity has enormous health burden implications, particu-
larly when immune responses to the biggest killers in the
developing world, i.e. HIV, tuberculosis and diarrhoeic
infections are affected.57 A number of mechanisms of
immune suppression of co-infections are at play here,
including the impairment of mucosal mastocytosis,58,59
the ablation of protective CD8+ T-cell responses,60 the
induction or alteration of regulatory T-cell subsets56,61
and the alternative activation of colonic macrophages62
(Fig. 2).
Apart from an impact on immune responses to pri-
mary infection, the presence of chronic parasite infection
in endemic areas has important implications for vaccina-
tion in the developing world. Epidemiological studies
have demonstrated that human helminth infections can
impair immune responses to tetanus toxoid and cholera
toxin B in endemic areas.63,64 In murine and large animal
models, helminth infection reduces the immune response
to malaria and Salmonella vaccinations.65–67 As described
previously, and in common with virus-induced immune
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suppression, these effects are related to the production of
regulatory cytokines such as IL-10 or the induction of
regulatory T cells during chronic parasite infection.
A number of chronic parasites, including Schistosoma
haematobium, Opisthorchis viverrini and Clonorchis
sinensis, are also classified as Group 1 carcinogens, pre-
senting a pertinent health challenge in developing regions.
In parasite endemic regions, infection with Schistosoma
mansoni and Schistosoma japonicum resulted in schistoso-
mal colitis and was linked to increased bladder and cervi-
cal cancer.68–70 Studies in vitro have shown that the
production of signature cytokines associated with murine
Heligmosomoides polygyrus infection or S. mansoni egg
administration promoted the replication of a herpesvirus
that drives cancer (Kaposi’s sarcoma)71 and recent epi-
demiological studies associated soil-transmitted helminth
infection with an increased prevalence of human papillo-
mavirus (a major cause of cervical cancer).72 In mouse
models, infection with the gastrointestinal helminth
H. polygyrus substantially reduced the type 1 inflamma-
tory response associated with Helicobacter pylori infection
and attenuated gastric atrophy, a pre-malignant lesion.46
Infection with the extraintestinal tapeworm Taenia crassi-
ceps reduced the development of colitis-associated
tumours in a murine model of colorectal cancer. This
effect was associated with increased expression of the type
2 cytokine IL-4 and with alterations in innate immunity,
including macrophage alternative activation, neutrophil
attraction and the recruitment of inflammatory mono-
cytes.73
In a similar manner to chronic viral infections, hel-
minths have evolved potent mechanisms to regulate the
host immune response, in order to ensure their long-term
survival.74 As well as notable effects on specific anti-para-
site responses, helminth immune regulation is proposed
to exert mutualistic symbiosis, similar to the chronic viral
infections discussed in the previous section, to further
benefit the host – by suppressing responses to a number
of allergens and autoantigens.75 Numerous studies have
employed murine models of inflammatory disease to
demonstrate that live parasite infection can protect
against inflammatory disorders through immunomodula-
tory mechanisms including the activation of regulatory T
cells46,49 or the production of IL-10.50 However, the
immune-regulatory pathways that live helminths employ
to modulate inflammatory disease are multi-faceted,
impacting on B cells,76 macrophages,77 innate immunity78
and through alterations to intestinal microbiota and their
metabolites.79,80
In epidemiological studies, the story is more complex.
Some studies have shown clear protection against allergen
skin test reactivity in individuals infected with intestinal
helminth infections such as Ascaris lumbricoides, Trichuris
trichiura, hookworm and schistosomiasis.81,82 This protec-
tion from pathology is associated with helminth-induced
polarization of the inflammatory cytokine response, in a
similar manner to chronic viral infections (as discussed in
the previous section). A correlation between parasite
infection and improvements in multiple sclerosis was
associated with increased frequencies of
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Figure 2. The good (light) and bad (dark) side of chronic parasite
infection. Chronic parasite infection can alter the commensal flora
of the gut, resulting in reduced airway inflammation/allergy and
inflammatory bowel disease. Parasite transforming growth factor-b
homologues (pTGF-b) released into the host can promote regulatory
T (Treg) cell expansion and up-regulation of programmed cell death
protein 1 (PD-1), which inhibit CD4+ T-cell expansion and inflam-
matory cell production, resulting in reduced autoimmunity and
allergy. Infection also promotes interleukin-10 (IL-10) production in
the host, which can also promote Treg and reduce inflammation.
Some helminth infections can promote the expansion of T cells pro-
ducing IL-22 (Th22 cells), which are able to promote homeostasis of
the gut epithelial lining, reducing inflammatory bowel disease.
Finally, infection is also able to promote the formation of B cells,
which can regulate inflammatory disorder such as asthma (regulatory
B cells). On the bad side, parasite infection promotes Treg cells,
which can reduce the efficacy of vaccines and the immune response
to other infections. Here, IL-10 produced in the host in response to
infection can also promote these Treg cells. Infection with parasites
can ablate protective CD8+ T-cell responses against co-infections
such as Toxoplasma gondii. The alternative activation of macrophages
promoted by parasite infection can also impair host protection
against concurrent bacterial infection.
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CD4+ CD25+ Foxp3+ T cells and increased cellular pro-
duction of the immune-regulatory cytokines IL-10 and
transforming growth factor-b.83 Resolution of colitis in
an individual who infected himself with T. trichiura84 was
associated with an increase in IL-22-producing CD4+
cells.85 Interestingly, prior parasite infection can mould
subsequent immune responses in the long-term; both
increased atopy and eczema were recorded in patients
from a parasite endemic region that were treated in a
long-term intervention study using the antihelminthic
ivermectin.86 Use of the antihelminthics albendazole and
praziquantal during pregnancy was also associated with
an increase rick of eczema in infancy,87,88 suggesting that
in utero helminth exposure may programme and prime
the host immune system of the offspring. These studies
clearly demonstrate that helminths can mould the gen-
ome of the host, similar to the chronic viral infections
discussed in the previous section. Perhaps the best exam-
ple of this for helminth infections is the selection of sickle
cells traits, which confer resistance to malaria in endemic
regions.89
Live helminths are currently being employed in a num-
ber of clinical trials in efforts to alleviate allergic and
autoimmune disorders.90 Successful trials include the
treatment of patients with inflammatory bowel disease
with eggs from the porcine whipworm Trichuris suis.91,92
However, not all trials using this strategy have had such a
profound outcome, as evidenced by repeated treatment of
patients exhibiting grass pollen-induced allergic rhinitis
with T. suis ova.93 The effectiveness of using parasitic hel-
minth infections to treat inflammatory disorders is called
into question in a recent review.94 This publication dis-
cusses the limitations of our current understanding of
host–parasite interactions and cites evidence of causal
associations between helminth infections and inflamma-
tory disorders. Recent reviews have also revealed the limi-
tations of human studies in poor-resource settings,95 and
indeed the consensus calls for the identification of hel-
minth-derived molecules of therapeutic potential and the
use of animal models, alongside appropriately controlled
clinical trials, to test these novel treatments of inflamma-
tory disease.
Some progress has already been made on this front;
individual helminth-secreted products from the human
hookworm Necator americanus, the filarial nematode
Acanthocheilonema viteae and the murine gastrointestinal
helminth H. polygyrus all suppressed rodent models of
inflammatory disease, including arthritis, allergy and
asthma.96,97,98 Each of these parasite-derived products has
a unique capacity to modulate the host immune system
at many levels, including suppression of mast cell
responses,99 dampening the activation of inflammatory T
cells by dendritic cells96 and by promoting the induction
of regulatory T cells.100 Our increasing understanding of
helminth modulation of immune function, has also led to
the proposal that helminth-treated populations of cells,
such as macrophages, be used in therapeutic applications
for inflammatory diseases in humans.101 These results
warrant further studies in animal models and possible
clinical trials to determine the efficacy of these findings in
humans.
In conclusion, both chronic viral and parasite infec-
tions can have both a beneficial and detrimental impact
on the host immune system. A consensus on one con-
served mechanism of immune suppression has not been
reached, although this is mainly due to the complexity of
the immune response, the tissue specificity of infection
and the underlying health status of the individual. As for
chronic viral infections, intestinal parasites have moulded
our genome and have an intimate bi-directional relation-
ship with the host. Our increasing understanding of host–
pathogen interactions and the complexity of our micro-
and macro-biome will enhance our ability to break the
bad consequences of chronic infection and make good
through tailored treatment of an individual with an
inflammatory disorder, or the development of strategies
that increase vaccine efficacy and limit infection-asso-
ciated tumour prevalence, in endemic regions.
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